MedTrace Logo

Improving Social Communication in Individuals With ASD Using AI

NCT05987774 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2026-08-10

No results posted yet for this study

Summary

The purpose of this study is to identify whether researched and commonly used face-to-face interventions can be effectively implemented through artificial intelligence (AI) using an application on the phone or computer. The investigators plan to recruit individuals diagnosed with autism spectrum disorder who demonstrate challenges with social communication. Modules focusing on various difficulties experienced by autistic individuals will provide practice and feedback using voice recognition and feedback. If effective, this intervention can be scaled up to provide cost-effective accessible assistance to individuals, particularly those who do not have access to care or prefer to secure services in the comfort of their own homes.

Conditions

Interventions

DEVICE

AI Modules for Improving Social Communication

The modules will be accessed via a web app. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results). The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include: Learning First Words, Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the Right Amount, Giving the Right Amount of Personal Information, Tactful Responses, Giving Compliments, and Staying On Topic During Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder. AI modules consist of thousands of total training examples. Participants may access the modules on their phones, tablets, or computers.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-15
Primary Completion
2027-06-30
Completion
2050-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05987774 on ClinicalTrials.gov